Back to top
more

LeMaitre Vascular (LMAT)

(Real Time Quote from BATS)

$102.40 USD

102.40
141,424

+3.77 (3.82%)

Updated Nov 6, 2024 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks News

ESLOY vs. LMAT: Which Stock Should Value Investors Buy Now?

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

ESLOY or LMAT: Which Is the Better Value Stock Right Now?

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LeMaitre Vascular (LMAT) Q3 Earnings Expected to Decline

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Q3 Earnings and Revenues Surpass Estimates

Abbott (ABT) delivered earnings and revenue surprises of 26.37% and 8.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?

ZBH vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular (LMAT) Lags Q2 Earnings Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.38% and 2.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of -3.57% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Misses Q4 Earnings and Revenue Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.68% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Q4 Earnings Lag Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of -14.89% and 1.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AHCO vs. LMAT: Which Stock Should Value Investors Buy Now?

AHCO vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular (LMAT) Lags Q3 Earnings and Revenue Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of -9.09% and -2.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate LeMaitre Vascular (LMAT) to Report a Decline in Earnings: What to Look Out for

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is ProShares Russell 2000 Dividend Growers ETF (SMDV) a Strong ETF Right Now?

Smart Beta ETF report for SMDV

Is ProShares Russell 2000 Dividend Growers ETF (SMDV) a Strong ETF Right Now?

Smart Beta ETF report for SMDV

LeMaitre Vascular (LMAT) Beats Q2 Earnings Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 17.65% and -0.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

LeMaitre Vascular (LMAT) to Report Q2 Results: Wall Street Expects Earnings Growth

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LeMaitre Vascular (LMAT) Recently Broke Out Above the 20-Day Moving Average

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

LeMaitre Vascular (LMAT) Matches Q1 Earnings Estimates

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and 0.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Earnings and Revenues Beat Estimates in Q1

Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.

Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates

Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.